Celcuity (CELC) said Monday it was granted a new patent covering the clinical dosing regimen for gedatolisib, its drug candidate for estrogen receptor-positive, HER2-negative breast cancer.
The new issuance brought to 13 the gedatolisib-related patents in the US and extended exclusivity in the US into 2042, according to the company.
Celcuity said it expects to report topline data for the PIK3CA wild-type cohort of its phase 3 trial of gedatolisib in Q3, and for the PIK3CA mutant cohort in Q4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.